Kalvista Pharmaceuticals Stock Current Valuation
| KALV Stock | USD 11.89 0.11 0.92% |
Valuation analysis of Kalvista Pharmaceuticals helps investors to measure Kalvista Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Kalvista Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Kalvista Pharmaceuticals is based on 3 months time horizon. Increasing Kalvista Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Kalvista stock is determined by what a typical buyer is willing to pay for full or partial control of Kalvista Pharmaceuticals. Since Kalvista Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kalvista Stock. However, Kalvista Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.89 | Real 9.41 | Hype 11.89 | Naive 11.52 |
The intrinsic value of Kalvista Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kalvista Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kalvista Pharmaceuticals helps investors to forecast how Kalvista stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kalvista Pharmaceuticals more accurately as focusing exclusively on Kalvista Pharmaceuticals' fundamentals will not take into account other important factors: Kalvista Pharmaceuticals Company Current Valuation Analysis
Kalvista Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kalvista Pharmaceuticals Current Valuation | 344.69 M |
Most of Kalvista Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kalvista Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Kalvista Pharmaceuticals has a Current Valuation of 344.69 M. This is 97.6% lower than that of the Biotechnology sector and 92.58% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.93% higher than that of the company.
Kalvista Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kalvista Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kalvista Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kalvista Pharmaceuticals by comparing valuation metrics of similar companies.Kalvista Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Kalvista Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | 344.69 M | ||||
| Shares Outstanding | 49.72 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 98.64 % | ||||
| Number Of Shares Shorted | 5.83 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 107.42 X | ||||
| Gross Profit | (81.07 M) | ||||
| EBITDA | (134.28 M) | ||||
| Net Income | (126.64 M) | ||||
| Cash And Equivalents | 142.08 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 7.32 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 17.51 X | ||||
| Book Value Per Share | 2.93 X | ||||
| Cash Flow From Operations | (89.23 M) | ||||
| Short Ratio | 12.75 X | ||||
| Earnings Per Share | (3.77) X | ||||
| Target Price | 26.33 | ||||
| Number Of Employees | 150 | ||||
| Beta | 0.76 | ||||
| Market Capitalization | 591.12 M | ||||
| Total Asset | 235.4 M | ||||
| Retained Earnings | (469.73 M) | ||||
| Working Capital | 202.88 M | ||||
| Current Asset | 54.95 M | ||||
| Current Liabilities | 4.27 M | ||||
| Net Asset | 235.4 M |
About Kalvista Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kalvista Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kalvista Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kalvista Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.